Black Hawk Acquisition Corp

EX-4.6 2 blackhawk_ex4-6.htm EXHIBIT 4.6 Exhibit 4.6 FORM OF WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (II) TO THE EXTENT APPLICABLE…

S-4/A · 2026-08-03 · 0001829126-26-008251

EX-99.1 5 blackhawk_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROXY CARD Black Hawk Acquisition Corporation YOUR VOTE IS IMPORTANT THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS The undersigned, revoking any previous proxies, hereby acknowledges receipt of the Notice of Special Meeting of Stockholders (the “Notice”) and the Joint Proxy Statement/Consent Solicitation Statement/Prospectus (the “Proxy Statement”), and hereby appoints ___________ and ___________, and each of them independentl…

S-4/A · 2026-08-03 · 0001829126-26-008251

EX-99.1 3 blackhawkacq_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer Blackhawk, Calif., March 17, 2026 - Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corpo…

8-K · 2026-03-17 · 0001829126-26-002413

EX-99.1 7 blackhawk_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Black Hawk Acquisition Corporation and Vesicor Therapeutics, Inc. (as co-registrant) of the Registration Statement on Form S-4, File Number 333-292402, (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 (17 C.F.R. §230.438) of the…

S-4/A · 2026-01-23 · 0001829126-26-000475

EX-99.2 8 blackhawk_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Black Hawk Acquisition Corporation and Vesicor Therapeutics, Inc. (as co-registrant) of the Registration Statement on Form S-4, File Number 333-292402, (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 (17 C.F.R. §230.438) of the…

S-4/A · 2026-01-23 · 0001829126-26-000475

Exhibit 107 Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-4 Black Hawk Acquisition Corp. Table 1: Newly Registered and Carry Forward Securities N/A Line Security Security Notes Fee Amount Proposed Maximum Fee Amount Item Type Type …

S-4 · 2025-12-23 · 0001829126-25-010259